Sangamo Therapeutics filed for Chapter 11 bankruptcy and agreed to sell key assets through stalking horse bids, with Eli Lilly set to acquire Sangamo’s capsid delivery, zinc finger nuclease and modular integrase platforms plus the prion disease program ST-506. Astellas is lined up to take Sangamo’s Fabry disease asset, isaralgagene civaparvovec (ST-920). Sangamo said it will put substantially all assets up for sale while leaving out certain programs from the stalking horse transactions, including ST-503 for chronic neuropathic pain, giroctocogene fitelparvovec for hemophilia A, and regulatory T cell and cell-therapy assets. The restructuring underlines the financial and pipeline pressure facing earlier gene-editing platforms that failed to reach approvals at scale. The outcome reshapes the competitive gene-editing landscape by transferring foundational enabling technology and clinical programs to larger platform operators. It also signals to the market how quickly valuation can collapse when pipeline de-risks stall, even for historically pioneering genome-editing companies.